Other equities research analysts have also issued reports about the company. Peel Hunt restated a hold rating and issued a GBX 160 ($2.10) price target on shares of Vectura Group PLC in a research report on Wednesday, August 16th. Panmure Gordon restated a buy rating on shares of Vectura Group PLC in a research note on Wednesday, August 30th. Numis Securities Ltd restated a buy rating and set a GBX 205 ($2.70) price target on shares of Vectura Group PLC in a research note on Thursday, September 7th. Citigroup Inc. reduced their price objective on Vectura Group PLC from GBX 200 ($2.63) to GBX 180 ($2.37) and set a buy rating on the stock in a research note on Monday, September 18th. Finally, J P Morgan Chase & Co cut their price target on Vectura Group PLC from GBX 210 ($2.76) to GBX 180 ($2.37) and set an overweight rating on the stock in a research note on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. The company has an average rating of Buy and a consensus price target of GBX 189.67 ($2.49).
Shares of Vectura Group PLC (LON:VEC) opened at GBX 90 ($1.18) on Thursday. Vectura Group PLC has a 1 year low of GBX 86.50 ($1.14) and a 1 year high of GBX 166.97 ($2.20).
In other Vectura Group PLC news, insider Bruno Angelici bought 70,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was acquired at an average cost of GBX 99 ($1.30) per share, with a total value of £69,300 ($91,148.23). Also, insider Andrew Derodra bought 82,000 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The shares were acquired at an average cost of GBX 90 ($1.18) per share, with a total value of £73,800 ($97,066.95). In the last quarter, insiders have purchased 152,456 shares of company stock worth $14,354,880.
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.